Print  |  Close

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer


Active: No
Cancer Type: Breast Cancer NCT ID: NCT04191499
Trial Phases: Phase II
Phase III
Protocol IDs: WO41554 (primary)
NCI-2020-02312
2019-002455-42
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Hoffmann-La Roche
NCI Full Details: http://clinicaltrials.gov/show/NCT04191499

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in
combination with palbociclib and fulvestrant compared with placebo plus palbociclib and
fulvestrant in participants with PIK3CA-mutant, hormone receptor (HR)-positive,
HER2-negative locally advanced or metastatic breast cancer whose disease progressed
during treatment or within 12 months of completing adjuvant endocrine therapy and who
have not received prior systemic therapy for metastatic disease.

Treatment Sites in Georgia

Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
144 Bill Carruth Parkway
Suite 3100
Hiram, GA 30141
770-281-5131
www.ngoc.com



Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
157 Clinic Avenue
Suite 101 and Suite 102
Carrollton, GA 30117
770-281-5101
www.ngoc.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.